Veeva
Systems (NYSE:VEEV)
What:
Veeva
Systems (NYSE:VEEV) will host the 2019
Veeva R&D Summit, Europe for more than 600 life sciences
professionals and industry experts from over 145 companies registered to
attend, making it the largest Veeva R&D Summit in Europe to date.
Keynotes and breakout sessions will showcase the latest advancements for
unifying systems and processes in clinical, regulatory, and quality for
faster product development.
Keynote Speakers:
-
Dr. Jacques Mascaro, senior vice president and head of regulatory
affairs and R&D quality at the Healthcare business of the Merck Group -
Professor Mike Stroud OBE, explorer and expert on human health under
extreme conditions who is recognized for his record-breaking
expeditions with Sir Ranulph Fiennes - Chris Moore, president of Veeva Europe
Sessions and Themes:
The event will offer 34 sessions with more than 50 speakers, including
leading global pharmaceutical companies and emerging biotechs such as
Bayer, Horizon, and UCB. Featured sessions on optimizing trial
performance, modernizing quality management, and transforming regulatory
operations include:
-
AstraZeneca sharing best practices for modernizing clinical
operations and streamlining trial execution with a unified suite of
applications. -
Novo Nordisk explaining how they modernized and simplified a
fragmented system landscape for controlled content management –
eliminating IT risks and gaining greater business value. -
GE Healthcare discussing lessons learned in regulatory
transformation, from improving the planning process to streamlining
cross-functional business processes and measuring success.
When:
June 11-13 in Barcelona, Spain
Where:
Garden Level Palau de Congressos de Catalunya
Sponsors:
2019 Veeva R&D Summit, Europe is sponsored by Accenture, NNIT, Valiance,
CGI, Eagle Productivity Solutions, Ernst & Young, fme AG, PwC Germany,
SDL, BASE life science, Deloitte, Epista Life Sciences, Ideagen,
INCONSULT, Kinapse, and LPW Training.
Who:
Veeva Systems Inc. is the leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva serves more than 750 customers, including 430+
Veeva Development Cloud customers, 265+ Vault Clinical customers, 180+
Vault RIM customers, 220+ Vault Quality customers, and 180+ customers
using multiple Veeva Vault applications. Veeva customers range from
emerging biotechs to the world’s top 20 largest biopharmaceutical
companies, including Vault Clinical (12 of top 20), Vault RIM (7 of top
20), and Vault Quality (10 of top 20). Veeva is headquartered in the San
Francisco Bay Area, with offices throughout North America, Europe, Asia,
and Latin America. For more information, visit veeva.com.
Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow
@veevasystems on Twitter: twitter.com/veevasystems
Like
Veeva on Facebook: facebook.com/veevasystems
Forward-looking Statements
This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended April 30, 2019. This is available on the
company’s website at veeva.com under
the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005916/en/